Exenatide - Newron Sweden
Alternative Names: Exendin-4 - NeuroNova ABLatest Information Update: 02 Oct 2021
At a glance
- Originator NeuroNova AB
- Developer Newron Sweden AB
- Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 13 Sep 2013 Discontinued - Preclinical for Parkinson's disease in Sweden (Parenteral)
- 21 Oct 2009 Pharmacodynamics data from animal studies in Parkinson's disease presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
- 31 Oct 2006 NeuroNova AB is seeking partnership opportunities to develop exenatide for Parkinson's disease